ClariTrial | Search Clinical Trials

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

38 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

MB-CART19.1 in Refractory SLE

Phase 1Phase 2SLE - Systemic Lupus Erythematosus

MB-CART19.1

Miltenyi Biomedicine GmbH29 participants3 sites · GermanyCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Phase 2Giant Cell Arteritis (GCA)

TocilizumabDiscontinue Tocilizumab

National Institute of Allergy and Infectious Diseases (NIAID)78 participants7 sites · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Phase 3Rheumatoid Arthritis

MethotrexateAbataceptAdalimumab+13 more

University of Nebraska400 participants1 site · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Phase 2Primary Immunodeficiency (PID)Congenital Bone Marrow Failure SyndromesInherited Metabolic Disorders (IMD)

HydroxyureaAlemtuzumabFludarabine+2 more

Paul Szabolcs100 participants1 site · United StatesCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Phase 2Multiple SclerosisClinically Isolated Syndrome of Demyelination

Tyruko Injectable ProductPlacebo

Queen Mary University of London40 participants2 sites · United KingdomCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Phase 2Glomerulonephritis Rapidly Progressive

ALE.F02RituximabGlucoCorticoid+3 more

Alentis Therapeutics AG80 participants49 sites · Czechia, Denmark, FranceCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Phase 2IgG4 Related DiseaseB-cell Mediated Autoimmune Disorders

Anti-BCMA-CD19 CAR-T cells

Chinese PLA General Hospital9 participants1 site · ChinaCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Phase 2Phase 3Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus

LitifilimabPlacebo

Biogen450 participants310 sites · United States, Argentina, BelgiumCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus

Phase 3Systemic Lupus Erythematosus

TelitaciceptInterleukin-2

Liu Tian60 participants1 site · ChinaCompletes Jul 2025

Compare CT.gov Full analysis →

Recruiting

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

Phase 2Rheumatoid Arthritis (RA)Rheumatology

dnaJP1Placebo

Prof Salvatore Albani124 participants1 site · SingaporeCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Alopecia Areata

Ruxolitinib

National Institute of Allergy and Infectious Diseases (NIAID)70 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Belimumab in Autoimmune Hepatitis

Phase 2Autoimmune Hepatitis

Belimumab Auto-Injector [Benlysta]

University Health Network, Toronto48 participants5 sites · CanadaCompletes Apr 2028

Compare CT.gov Full analysis →

Recruiting

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Phase 3Immunoglobulin A Nephropathy (IgAN)

FelzartamabPlacebo

Biogen454 participants222 sites · United States, Argentina, AustraliaCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

Phase 3Lupus Nephritis

Voclosporin（QL1074）Placebo

Qilu Pharmaceutical Co., Ltd.270 participants10 sites · ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Phase 2Lymphoproliferative DisordersAutoimmune LymphoproliferativeImmune System Diseases

Busulfan test doseFludarabineBusulfan+6 more

National Cancer Institute (NCI)66 participants1 site · United StatesCompletes Oct 2026

Compare CT.gov Full analysis →

1–15 of 38

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

38 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

MB-CART19.1 in Refractory SLE

Phase 1Phase 2SLE - Systemic Lupus Erythematosus

MB-CART19.1

Miltenyi Biomedicine GmbH29 participants3 sites · GermanyCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Phase 2Giant Cell Arteritis (GCA)

TocilizumabDiscontinue Tocilizumab

National Institute of Allergy and Infectious Diseases (NIAID)78 participants7 sites · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Phase 3Rheumatoid Arthritis

MethotrexateAbataceptAdalimumab+13 more

University of Nebraska400 participants1 site · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Phase 2Primary Immunodeficiency (PID)Congenital Bone Marrow Failure SyndromesInherited Metabolic Disorders (IMD)

HydroxyureaAlemtuzumabFludarabine+2 more

Paul Szabolcs100 participants1 site · United StatesCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Phase 2Multiple SclerosisClinically Isolated Syndrome of Demyelination

Tyruko Injectable ProductPlacebo

Queen Mary University of London40 participants2 sites · United KingdomCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Phase 2Glomerulonephritis Rapidly Progressive

ALE.F02RituximabGlucoCorticoid+3 more

Alentis Therapeutics AG80 participants49 sites · Czechia, Denmark, FranceCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Phase 2IgG4 Related DiseaseB-cell Mediated Autoimmune Disorders

Anti-BCMA-CD19 CAR-T cells

Chinese PLA General Hospital9 participants1 site · ChinaCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Phase 2Phase 3Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus

LitifilimabPlacebo

Biogen450 participants310 sites · United States, Argentina, BelgiumCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus

Phase 3Systemic Lupus Erythematosus

TelitaciceptInterleukin-2

Liu Tian60 participants1 site · ChinaCompletes Jul 2025

Compare CT.gov Full analysis →

Recruiting

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

Phase 2Rheumatoid Arthritis (RA)Rheumatology

dnaJP1Placebo

Prof Salvatore Albani124 participants1 site · SingaporeCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Alopecia Areata

Ruxolitinib

National Institute of Allergy and Infectious Diseases (NIAID)70 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Belimumab in Autoimmune Hepatitis

Phase 2Autoimmune Hepatitis

Belimumab Auto-Injector [Benlysta]

University Health Network, Toronto48 participants5 sites · CanadaCompletes Apr 2028

Compare CT.gov Full analysis →

Recruiting

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Phase 3Immunoglobulin A Nephropathy (IgAN)

FelzartamabPlacebo

Biogen454 participants222 sites · United States, Argentina, AustraliaCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

Phase 3Lupus Nephritis

Voclosporin（QL1074）Placebo

Qilu Pharmaceutical Co., Ltd.270 participants10 sites · ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Phase 2Lymphoproliferative DisordersAutoimmune LymphoproliferativeImmune System Diseases

Busulfan test doseFludarabineBusulfan+6 more

National Cancer Institute (NCI)66 participants1 site · United StatesCompletes Oct 2026

Compare CT.gov Full analysis →

1–15 of 38